Drugs

Prof Brian Kennedy: Talking biomarkers and interventions

“We're not trying to make billionaires live longer, we're trying to make everybody live longer.” When it comes to thought leaders in the Longevity sector,...

Elysium announces epigenetic aging clinical trial

Elysium Health is to study correlations between epigenetic aging and amounts of NAD+ and other biomarkers in a new clinical trial. Fresh on the back...

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

2020 outlook for Longevity technology

Will 2020 be the year that sees a step change in Longevity? We review technology readiness levels for key Longevity domains. Yep, we have a...

Latest articles

Insurer puts down £20m to research an aging rethink

A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society. The world is...

23andMe redundancies: DNA test market decline?

Could layoffs at 23andMe be a sign that the consumer appetite for genetic testing is declining? We expect consumer markets to transition to more...

Singapore agetech – ones to watch in 2020

Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.